Harmony Biosciences to be Added to the S&P SmallCap 600® Index
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced its addition to the S&P SmallCap 600 Index, effective October 22, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced its addition to the S&P SmallCap 600 Index, effective October 22, 2021. This milestone is seen as a recognition of the company's efforts in providing innovative therapies for rare neurological diseases. The index measures the performance of 600 small-cap U.S. companies, requiring a market cap between $850 million and $3.6 billion. CEO John C. Jacobs expressed confidence that this inclusion will enhance the company's visibility and awareness among stakeholders.
Positive
- Addition to the S&P SmallCap 600 Index enhances visibility.
- Recognition reflects the company's commitment to rare neurological diseases.
Negative
- None.
Details
News Market Reaction – HRMY
The recorded move for HRMY in the trading session of this news was -2.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PLYMOUTH MEETING, Pa., Oct. 21, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will be added to the S&P SmallCap 600® Index, effective prior to the open of trading on Friday, October 22, 2021.
"We are very pleased that Harmony will be included in the S&P SmallCap 600® Index and are proud of this recognition," said John C. Jacobs, President and Chief Executive Officer of Harmony. "We believe the inclusion in the index will increase our visibility and raise awareness of the work we are doing to help patients, as we continue to build a leading rare neurological disease company."
The S&P 600® seeks to measure the small-cap segment of the U.S. equity market. The index is designed to measure the performance of 600 small-cap companies in the U.S. reflecting this market segment's distinctive risk and return characteristics. To be included, companies must have an unadjusted market cap in the range of
About Harmony Biosciences
Harmony Biosciences is a commercial stage pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, and is focused on providing novel treatment options for people living with rare neurological diseases who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.
Harmony Biosciences Investor Contact:
Patti Bank
415-513-1284
ir@harmonybiosciences.com
Harmony Biosciences Media Contact:
Nancy Leone
215-891-6046
nleone@harmonybiosciences.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-be-added-to-the-sp-smallcap-600-index-301405226.html
SOURCE Harmony Biosciences